uid stringclasses 10
values | dataset_id stringclasses 1
value | year int64 2.02k 2.02k | therapeutic_area stringclasses 6
values | program_stage stringclasses 1
value | efficacy_signal_present stringclasses 2
values | safety_margin_ok stringclasses 2
values | biomarker_support stringclasses 2
values | target_validity stringclasses 3
values | portfolio_fit stringclasses 2
values | team_narrative_strength stringclasses 10
values | question stringclasses 1
value | ground_truth_label stringclasses 2
values | ground_truth_rationale stringclasses 10
values | outcome_signal stringclasses 2
values | source_citation stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GN-TR-001 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,024 | Oncology | Phase2 | yes | yes | yes | strong | yes | Narrative matches data and portfolio need. | Should program proceed. Answer go or no_go. | go | Aligned biology and signal. | advance | Synthetic |
GN-TR-002 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,024 | Oncology | Phase2 | no | no | no | weak | no | Narrative optimistic despite weak data. | Should program proceed. Answer go or no_go. | no_go | Weak efficacy and safety. | terminate | Synthetic |
GN-TR-003 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,023 | Cardiology | Phase2 | yes | yes | yes | strong | yes | Signal consistent across endpoints. | Should program proceed. Answer go or no_go. | go | Consistent efficacy and safety. | advance | Synthetic |
GN-TR-004 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,023 | Cardiology | Phase2 | no | yes | no | medium | no | Marginal efficacy and no biomarker support. | Should program proceed. Answer go or no_go. | no_go | Insufficient benefit. | terminate | Synthetic |
GN-TR-005 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,022 | Neurology | Phase2 | yes | yes | yes | strong | yes | Clear responder subgroup. | Should program proceed. Answer go or no_go. | go | Signal in enriched population. | advance | Synthetic |
GN-TR-006 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,022 | Neurology | Phase2 | no | no | no | weak | no | No clinical improvement. | Should program proceed. Answer go or no_go. | no_go | No signal present. | terminate | Synthetic |
GN-TR-007 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,021 | Rheumatology | Phase2 | yes | yes | yes | strong | yes | Dose response and safety acceptable. | Should program proceed. Answer go or no_go. | go | Aligned package. | advance | Synthetic |
GN-TR-008 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,021 | Rheumatology | Phase2 | no | yes | no | weak | no | Minimal improvement. | Should program proceed. Answer go or no_go. | no_go | No meaningful efficacy. | terminate | Synthetic |
GN-TR-009 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,020 | Infectious Disease | Phase2 | yes | yes | yes | strong | yes | Strong pathogen clearance. | Should program proceed. Answer go or no_go. | go | Clear benefit. | advance | Synthetic |
GN-TR-010 | pharma-program-go-no-go-coherence-risk-v0.1 | 2,020 | Metabolic | Phase2 | no | no | no | weak | no | No glucose control improvement. | Should program proceed. Answer go or no_go. | no_go | No efficacy. | terminate | Synthetic |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.